SK Biopharm disclosed Thursday that its third-quarter consolidated operating profit rose 65.9% from a year earlier to 116.28 billion won ($86.7 million).
Revenue for the same period climbed 34.8% to 258.42 billion won.
Net profit for the period fell 23.9% to 54.34 billion won, according to preliminary figures.
jiyoon436@heraldcorp.com
